Table 3.
PAC-1 activity in pancreatic and other gastrointestinal NETs.
| NET type | Metastases | Grade | Ki-67 (%) | Prior therapy #1 | Duration #1 | Reason to stop therapy | BR to #1 therapy | Prior therapy #2 | Duration #2 | Reason to stop therapy | BR to #2 therapy | Duration of PAC-1 | Reason to stop therapy | BR on PAC-1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pancreatic | Liver | 1 | 1 | Sunitinib | 4.5 | PD (283%) | 16% | Immunotherapy | 2 | Toxicity | −9% | 8 | PD | −64.3% |
| Gastrointestinal | Peritoneal | 2 | 7 | Cabozantinib/lanreotide | 5.5 | Anorexia, nausea | 6% | Everolimus | 3 | PD | 12% | 10 | PD | –2.5% |
| Colon | Liver | 1 | 1 | Everolimus | 5.5 | Nausea, dizziness | 17% | 6 | PD | 6% | ||||
| Pancreatic | Liver | 2 | 10 | Everolimus | 6 | PD | 24% | Sunitinib | 5 | PD | 15% | 4 | PD | 3.9% |
| Ileal | Mesenteric | 2 | 5 | Sunitinib/octreotide | 1.5 | PD | 28% | Everolimus/octreotide | 2 | Renal toxicity | 14% | 4 | Intestinal obstruction | −36% |
BR best response, NET neuroendocrine tumour, PAC-1 first procaspase-activating compound, PD progressive disease.